Capital Fund Management (CFM)
TXG icon

Capital Fund Management (CFM)’s 10x Genomics TXG Stock Holding History

Capital Fund Management (CFM)’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-24,400
Closed -$1.01M – 2302
2023
Q3 		$1.01M Buy
+24,400
New +$1.27M ﹤0.01% 1644

Other funds holding TXG

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Fund Management (CFM)'s TXG Position: Q4 2025 in Review

Capital Fund Management (CFM) sold out of 10x Genomics (TXG) in Q4 2025, closing a stake of 76,493 shares — an estimated $894K sold.

Capital Fund Management (CFM) first reported a position in TXG in Q3 2021 and held it in 7 quarters. The position peaked at $5.05M in Q3 2024. 322 funds tracked by Wall St. Rank hold TXG as of Q4 2025.

  • Capital Fund Management (CFM) reported no remaining 10x Genomics position as of Q4 2025 after selling out during the quarter.
  • Capital Fund Management (CFM) sold 76,493 10x Genomics shares in Q4 2025, an estimated $894K.
  • Capital Fund Management (CFM) first reported a position in 10x Genomics in Q3 2021 and held it in 7 quarters.
  • Capital Fund Management (CFM)'s 10x Genomics position peaked at $5.05M in Q3 2024.
  • 322 funds tracked by Wall St. Rank held 10x Genomics as of Q4 2025.

Based on Capital Fund Management (CFM)'s 13F filing for Q4 2025, filed 17 Feb 2026.